| Literature DB >> 30139895 |
Anna Regina Schandl1, Asif Johar1, Kalle Mälberg1, Pernilla Lagergren1.
Abstract
OBJECTIVE: The purpose of the study was to investigate whether low education level was associated with patients' health-related quality of life (HRQOL) after oesophageal cancer resection.Entities:
Keywords: cancer survivorship; hrqol; long-term follow-up; oesophageal neoplasm
Mesh:
Year: 2018 PMID: 30139895 PMCID: PMC6112400 DOI: 10.1136/bmjopen-2017-020702
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Patient, tumour and therapy characteristics of 378 patients 6 months after oesophageal cancer surgery, categorised by education level
| Education level | ||
| High (≥10 years) | Low (≤9 years) | |
| Total | 204 | 174 |
| Gender | ||
| Men | 162 (79) | 145 (83) |
| Women | 42 (21) | 29 (17) |
| Age at surgery (years) | ||
| <60 | 68 (33) | 26 (15) |
| 60–74 | 112 (55) | 108 (62) |
| ≥75 | 24 (12) | 40 (23) |
| No of comorbidities | ||
| 0 | 131 (64) | 85 (49) |
| ≥1 | 73 (36) | 89 (51) |
| Body mass index (kg/m2) | ||
| ≥25 | 104 (51) | 82 (47) |
| <25 | 100 (49) | 92 (53) |
| Tumour histology | ||
| Squamous cell carcinoma | 44 (22) | 43 (25) |
| Adenocarcinoma | 160 (78) | 131 (75) |
| Tumour location | ||
| Upper/middle oesophagus | 26 (13) | 30 (17) |
| Lower oesophagus or cardia | 178 (87) | 144 (83) |
| Pathological tumour stage | ||
| 0–I | 48 (24) | 31 (18) |
| II | 62 (30) | 52 (30) |
| III | 76 (37) | 78 (45) |
| IV | 18 (9) | 13 (7) |
| Neoadjuvant therapy | ||
| No | 191 (94) | 164 (94) |
| Yes | 13 (6) | 10 (6) |
| Surgical approach | ||
| Transthoracic | 173 (85) | 146 (84) |
| Transhiatal | 31 (15) | 28 (16) |
| Postoperative complications | ||
| No | 139 (68) | 116 (67) |
| Yes | 65 (32) | 58 (33) |
Patient and tumour characteristics and health-related quality of life 3 years after oesophageal cancer surgery (n=172), categorised by educational level
| Education level | ||
| High (≥10 years) | Low (≤9 years) | |
| Total | 94 | 78 |
| Gender | ||
| Men | 73 (78) | 63 (81) |
| Women | 21 (22) | 15 (19) |
| Age at surgery (years) | ||
| <60 | 28 (30) | 16 (21) |
| 60–74 | 58 (62) | 50 (15) |
| ≥75 | 8 (9) | 12 (15) |
| No of comorbidities | ||
| 0 | 59 (63) | 35 (45) |
| ≥1 | 35 (37) | 43 (55) |
| Body mass index (kg/m2) | ||
| ≥25 | 54 (57) | 38 (49) |
| <25 | 40 (43) | 40 (51) |
| Tumour histology | ||
| Squamous cell carcinoma | 16 (17) | 23 (29) |
| Adenocarcinoma | 78 (83) | 55 (71) |
| Tumour location | ||
| Upper/middle oesophagus | 9 (10) | 14 (18) |
| Lower oesophagus or cardia | 85 (90) | 64 (82) |
| Pathological tumour stage | ||
| 0–I | 44 (47) | 26 (33) |
| II | 25 (27) | 31 (40) |
| III | 21 (22) | 17 (22) |
| IV | 4 (4) | 4 (5) |
| Neoadjuvant therapy | ||
| No | 91 (97) | 77 (99) |
| Yes | 3 (3) | 1 (1) |
| Surgical approach | ||
| Transthoracic | 72 (77) | 66 (85) |
| Transhiatal | 22 (23) | 12 (15) |
| Postoperative complications | ||
| No | 62 (66) | 50 (64) |
| Yes | 32 (34) | 28 (36) |
Mean score differences with 95% CIs in HRQOL between patients with high education level (≥10 years) versus low education level (≤9 years) 6 months and 3 years after oesophageal cancer surgery
| HRQOL aspect | Level of education | |||
| Six months | Three years | |||
| High | Low | High | Low | |
| Mean scores | Mean differences | Mean scores | Mean differences | |
| EORTC QLQ-C30 | ||||
| Global quality of life | 52 (45 to 59) | −3 (−8 to 1) | 59 (45 to 72) | −2 (−9 to 5) |
| Functional scales | ||||
| Physical | 72 (65 to 78) | −6 (−10 to −2) | 72 (60 to 84) | −1 (−7 to 6) |
| Role | 56 (45 to 66) | −8 (−15 to −1) | 69 (50 to 89) | −4 (−14 to 6) |
| Emotional | 65 (58 to 73) | −4 (−10 to 1) | 69 (56 to 82) | −5 (−12 to 2) |
| Cognitive | 79 (72 to 86) | −6 (−11 to −2) | 79 (67 to 91) | −3 (−9 to 4) |
| Social | 63 (54 to 73) | 1 (−5 to 7) | 71 (55 to 87) | −1 (−9 to 7) |
| Symptom scales | ||||
| Fatigue | 52 (44 to 60) | 7 (1 to 12) | 35 (19 to 52) | −2 (−10 to 7) |
| Nausea/vomiting | 24 (17 to 31) | 4 (−1 to 9) | 18 (5 to 32) | 3 (−4 to 10) |
| Pain | 25 (16 to 34) | 8 (2 to 14) | 22 (5 to 38) | 0 (−8 to 8) |
| Symptom items | ||||
| Dyspnoea | 41 (31 to 51) | 5 (-1 to 12) | 43 (25 to 62) | −2 (−11 to 8) |
| Insomnia | 29 (20 to 39) | 6 (0 to 12) | 36 (16 to 55) | 4 (−6 to 14) |
| Appetite loss | 44 (33 to 58) | 4 (−3 to 12) | 35 (15 to 55) | −8 (−18 to 2) |
| Constipation | 15 (7 to 22) | 4 (−1 to 8) | 16 (2 to 29) | −2 (−9 to 5) |
| Diarrhoea | 32 (22 to 42) | 4 (−2 to 11) | 32 (13 to 51) | −5 (−14 to 5) |
| Financial difficulties | 22 (13 to 30) | 6 (1 to 12) | 16 (2 to 29) | 8 (1 to 15) |
| EORTC QLQ-OES 18 | ||||
| Disease-specific symptom scales | ||||
| Dysphagia | 30 (22 to 38) | −1 (−7 to 5) | 19 (−1 to 39) | 8 (−2 to 18) |
| Reflux | 24 (15 to 33) | 4 (−2 to 10) | 21 (3 to 39) | 5 (−5 to 14) |
| Eating difficulties | 44 (36 to 52) | 1 (−4 to 7) | 31 (15 to 47) | −5 (−13 to 4) |
| Oesophageal pain | 26 (18 to 33) | 4 (−1 to 9) | 18 (5 to 32) | 5 (−1 to 12) |
| Disease-specific items | ||||
| Trouble swallowing saliva | 17 (9 to 26) | 2 (−3 to 8) | 6 (-11 to 22) | 3 (−5 to 11) |
| Choking | 22 (14 to 31) | 4 (−2 to 9) | 9 (-4 to 23) | 2 (−5 to 9) |
| Dry mouth | 28 (18 to 38) | 8 (1 to 14) | 20 (1 to 39) | 1 (−8 to 11) |
| Coughing | 30 (20 to 40) | −2 (−9 to 4) | 19 (1 to 36) | −7 (−16 to 2) |
| Speech difficulties | 21 (13 to 29) | −1 (−6 to 4) | 11 (−1 to 23) | 0 (−6 to 6) |
| Problems with taste | 32 (22 to 42) | 4 (−3 to 10) | 15 (−3 to 33) | 0 (−9 to 10) |
The models used to calculate mean scores and mean score differences were adjusted for age, sex, number of comorbidities, tumour stage, tumour histology, tumour location, body mass index ≥25 kg/m2 and postoperative complications. A mean score difference of ≥10 is considered clinically relevant and further tested for statistical significance.
EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; HRQOL, health-related quality of life; OES 18, oesophageal cancer-specific module.
Mean differences with 95% CIs in HRQOL between men and women with high education level (≥10 years) versus low education level (≤9 years) 6 months after oesophageal cancer surgery
| HRQOL aspect | Education level | P values | Education level | P values | Education level | P values | |||
| Low | Low | High | Low | High | Low | ||||
| Men n=145 | Women n=29 | Women n=42 | Women n=29 | Men n=162 | Men n=145 | ||||
| Mean scores | Mean differences (95% CI) | Mean scores | Mean differences (95% CI) | Mean scores | Mean differences (95% CI) | ||||
| EORTC QLQ-C30 | |||||||||
| Global quality of life | 48 (41 to 55) | −2 (−11 to 8) | 57 (48 to 66) | −10 (−21 to 0) | 0.05 | 50 (43 to 57) | −2 (−7 to 3) | ||
| Functional scales | |||||||||
| Physical | 65 (59 to 72) | −1 (−9 to 8) | 73 (65 to 82) | −8 (−18 to 2) | 71 (64 to 78) | −5 (−10 to 0) | |||
| Role | 46 (35 to 56) | 2 (−12 to 16) | 61 (47 to 75) | −13 (−29 to 3) | 0.12 | 53 (42 to 63) | −7 (−14 to 1) | ||
| Emotional | 64 (56 to 71) | −13 (−22 to −3) | 0.01 | 74 (64 to 83) | −22 (−34 to −11) | 0.0001 | 64 (57 to 71) | 0 (−6 to 5) | |
| Cognitive | 74 (67 to 80) | −7 (−16 to 2) | 86 (77 to 95) | −20 (−30 to −10) | 0.0002 | 77 (70 to 84) | −3 (−8 to 2) | ||
| Social | 64 (55 to 73) | −6 (−17 to 6) | 73 (61 to 84) | −14 (−28 to −1) | 0.03 | 60 (51 to 68) | 4 (−2 to 11) | ||
| Symptom scales | |||||||||
| Fatigue | 58 (50 to 66) | 3 (−7 to 14) | 47 (37 to 58) | 14 (1 to 26) | 0.03 | 53 (45 to 61) | 5 (−1 to 11) | ||
| Nausea/vomiting | 24 (17 to 32) | 8 (−2 to 17) | 27 (17 to 37) | 5 (−6 to 16) | 21 (13 to 28) | 4 (−1 to 9) | |||
| Pain | 34 (25 to 42) | 4 (−7 to 16) | 17 (5 to 28) | 21 (7 to 34) | 0.002 | 28 (19 to 37) | 5 (−2 to 12) | ||
| Symptom items | |||||||||
| Dyspnoea | 49 (39 to 58) | −5 (−17 to 8) | 38 (25 to 50) | 7 (−8 to 22) | 44 (34 to 54) | 5 (−2 to 12) | |||
| Insomnia | 28 (19 to 37) | 20 (8 to 32) | 0.01 | 26 (14 to 38) | 22 (8 to 36) | 0.002 | 26 (17 to 35) | 2 (−5 to 9) | |
| Appetite loss | 45 (34 to 56) | 12 (−3 to 26) | 0.12 | 40 (26 to 55) | 16 (−1 to 33) | 0.06 | 43 (32 to 54) | 2 (−7 to 10) | |
| Constipation | 17 (6 to 25) | 2 (−8 to 11) | 15 (6 to 25) | 4 (−8 to 15) | 14 (7 to 21) | 4 (−2 to 9) | |||
| Diarrhoea | 36 (26 to 46) | 4 (−9 to 17) | 29 (16 to 43) | 10 (−5 to 26) | 0.19 | 33 (23 to 43) | 3 (−4 to 11) | ||
| Financial difficulties | 27 (19 to 35) | 2 (−9 to 13) | 20 (9 to 31) | 9 (−3 to 22) | 22 (14 to 30) | 5 (−1 to 11) | |||
| EORTC QLQ-OES 18 | |||||||||
| Disease-specific symptom scales | |||||||||
| Dysphagia | 29 (20 to 37) | 5 (−6 to 16) | 26 (15 to 37) | 8 (−5 to 21) | 31 (23 to 40) | −2 (−9 to 4) | |||
| Reflux | 22 (13 to 31) | 15 (3 to 26) | 0.02 | 24 (12 to 36) | 13 (−1 to 26) | 0.06 | 20 (11 to 30) | 2 (−5 to 9) | |
| Eating difficulties | 45 (37 to 53) | 1 (−10 to 12) | 42 (31 to 53) | 4 (−8 to 17) | 45 (36 to 53) | 0 (−6 to 6) | |||
| Oesophageal pain | 28 (21 to 36) | 6 (−4 to 16) | 22 (12 to 32) | 12 (1 to 24) | 0.04 | 26 (18 to 34) | 2 (−3 to 8) | ||
| Disease-specific items | |||||||||
| Trouble swallowing saliva | 19 (11 to 27) | 2 (−9 to 13) | 17 (6 to 28) | 4 (−9 to 16) | 17 (9 to 25) | 2 (−4 to 8) | |||
| Choking | 26 (18 to 34) | 1 (−10 to 12) | 21 (10 to 32) | 5 (−7 to 18) | 23 (14 to 31) | 3 (−3 to 9) | |||
| Dry mouth | 34 (24 to 44) | 7 (−6 to 20) | 24 (11 to 38) | 17 (2 to 32) | 0.03 | 28 (18 to 38) | 6 (−2 to 13) | ||
| Coughing | 30 (20 to 40) | −6 (−19 to 7) | 29 (16 to 42) | −5 (−20 to 10) | 32 (22 to 42) | −2 (−9 to 6) | |||
| Speech difficulties | 24 (17 to 32) | −9 (−19 to 2) | 19 (8 to 29) | −3 (−15 to 9) | 25 (17 to 32) | 0 (−6 to 5) | |||
| Problems with taste | 36 (26 to 46) | 1 (−12 to 15) | 29 (16 to 42) | 9 (−7 to 24) | 33 (23 to 43) | 2 (−5 to 10) | |||
The models used to calculate mean scores and mean score differences were adjusted for age, number of comorbidities, tumour stage, tumour histology, tumour location, body mass index ≥25 kg/m2 and postoperative complications. A mean score difference of ≥10 is considered clinically relevant and further tested for statistical significance.
EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; HRQOL, health-related quality of life; OES 18, oesophageal cancer-specific module.
Mean score differences with 95% CIs in HRQOL between men and women with high education level (≥10 years) versus low education level (≤9 years) 3 years after oesophageal cancer surgery
| HRQOL aspect | Education level | P values | Education level | P values | Education level | P value | |||
| Low | Low | High | Low | High | Low | ||||
| Men n=63 | Women n=15 | Women n=21 | Women n=15 | Men n=73 | Men n=63 | ||||
| Mean scores | Mean differences (95% CI) | Mean scores | Mean differences (95% CI) | Mean scores | Mean differences (95% CI) | ||||
| EORTC QLQ-C30 | |||||||||
| Global quality of life | 59 (45 to 73) | −4 (−18 to 9) | 60 (43 to 76) | −6 (−21 to 10) | 60 (46 to 73) | −1 (−9 to 6) | |||
| Functional scales | |||||||||
| Physical | 74 (61 to 86) | −5 (−17 to 7) | 73 (58 to 88) | −5 (−18 to 9) | 73 (61 to 85) | 0 (–7 to 7) | |||
| Role | 71 (51 to 91) | −16 (−36 to 3) | 0.09 | 79 (55 to 102) | −25 (−46 to −3) | 0.03 | 70 (51 to 89) | 1 (–10 to 12) | |
| Emotional | 67 (53 to 80) | −8 (−21 to 5) | 74 (58 to 90) | −15 (−30 to 0) | 0.04 | 69 (56 to 82) | −2 (−10 to 5) | ||
| Cognitive | 79 (66 to 91) | −7 (−19 to 5) | 84 (69 to 98) | −12 (−25 to 2) | 0.10 | 79 (67 to 91) | 0 (–7 to 7) | ||
| Social | 74 (58 to 90) | −14 (−30 to 1) | 0.07 | 82 (63 to 100) | −22 (−39 to −4) | 0.01 | 70 (55 to 85) | 4 (–4 to 13) | |
| Symptom scales | |||||||||
| Fatigue | 31 (15 to 48) | 8 (–8 to 24) | 33 (13 to 52) | 6 (–11 to 24) | 35 (19 to 50) | −4 (−13 to 5) | |||
| Nausea/vomiting | 19 (5 to 33) | 5 (–8 to 19) | 21 (5 to 38) | 3 (–12 to 18) | 15 (2 to 29) | 3 (–4 to 11) | |||
| Pain | 20 (4 to 37) | 3 (–13 to 19) | 23 (3 to 43) | 0 (–18 to 18) | 20 (4 to 36) | 0 (–9 to 9) | |||
| Symptom items | |||||||||
| Dyspnoea | 43 (24 to 62) | −2 (−20 to 16) | 45 (22 to 67) | −4 (−25 to 19) | 43 (25 to 62) | −1 (−11 to 10) | |||
| Insomnia | 37 (17 to 57) | 4 (–15 to 23) | 43 (20 to 67) | −2 (−24 to 17) | 31 (12 to 51) | 6 (–5 to 17) | |||
| Appetite loss | 21 (1 to 42) | 17 (–3 to 36) | 0.10 | 27 (3 to 51) | 11 (–11 to 33) | 0.33 | 34 (14 to 53) | −12 (−23 to −1) | 0.03 |
| Constipation | 9 (–4 to 23) | 12 (–2 to 25) | 0.09 | 14 (–2 to 30) | 7 (–9 to 22) | 13 (0 to 26) | −4 (−11 to 4) | ||
| Diarrhoea | 29 (10 to 48) | −5 (−24 to 14) | 35 (12 to 57) | −11 (−32 to 11) | 0.32 | 32 (13 to 51) | −3 (−14 to 7) | ||
| Financial difficulties | 23 (9 to 37) | 4 (–9 to 18) | 11 (–6 to 27) | 17 (1 to 32) | 0.03 | 17 (3 to 30) | 6 (–2 to 14) | ||
| EORTC QLQ-OES 18 | |||||||||
| Disease-specific symptom scales | |||||||||
| Dysphagia | 25 (5 to 46) | 6 (–14 to 26) | 13 (–11 to 37) | 19 (–4 to 41) | 0.10 | 20 (1 to 40) | 5 (–6 to 16) | ||
| Reflux | 23 (4 to 42) | 3 (–15 to 21) | 27 (4 to 49) | 0 (–21 to 20) | 17 (–1 to 36) | 6 (–5 to 16) | |||
| Eating difficulties | 24 (7 to 41) | 7 (–10 to 23) | 30 (10 to 49) | 1 (–17 to 20) | 30 (14 to 46) | −6 (−15 to 3) | |||
| Oesophageal pain | 24 (11 to 38) | −3 (−17 to 10) | 22 (6 to 38) | −1 (−16 to 14) | 17 (4 to 31) | 7 (–1 to 15) | |||
| Disease-specific items | |||||||||
| Trouble swallowing saliva | 9 (–8 to 26) | −2 (−17 to 13) | 8 (-11 to 28) | −2 (−18 to 15) | 5 (–12 to 22) | 4 (–5 to 12) | |||
| Choking | 9 (–6 to 23) | 3 (–11 to 17) | 15 (–2 to 32) | −4 (−19 to 12) | 6 (–8 to 20) | 3 (–5 to 11) | |||
| Dry mouth | 14 (–6 to 34) | 14 (–6 to 33) | 0.16 | 27 (3 to 51) | 1 (–21 to 23) | 13 (–7 to 32) | 2 (–10 to 13) | ||
| Coughing | 10 (–8 to 28) | 5 (–13 to 22) | 16 (–5 to 38) | −1 (−21 to 18) | 18 (1 to 36) | −8 (−18 to 2) | |||
| Speech difficulties | 12 (–1 to 24) | −2 (15 to 10) | 12 (–3 to 26) | −3 (−16 to 11) | 11 (–1 to 23) | 0 (–6 to 7) | |||
| Problems with taste | 8 (–11 to 26) | 22 (4 to 40) | 0.02 | 11 (–11 to 32) | 19 (–1 to 39) | 0.07 | 12 (–6 to 29) | −4 (−14 to 6) | |
The models used to calculate mean scores and mean score differences were adjusted for age, number of comorbidities, tumour stage, tumour histology, tumour location, body mass index ≥25 kg/m2 and postoperative complications. Statistical significance was calculated only for clinically relevant differences.
EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; HRQOL, health-related quality of life; OES 18, oesophageal cancer-specific module.